MaxCyte, Inc. (LON:MXCT – Get Free Report) shares traded down 9.4% during mid-day trading on Thursday . The stock traded as low as GBX 230 ($2.98) and last traded at GBX 240 ($3.11). 86,242 shares traded hands during trading, an increase of 105% from the average session volume of 42,170 shares. The stock had previously closed at GBX 265 ($3.44).
MaxCyte Stock Up 7.4 %
The business has a 50-day moving average price of GBX 334.35 and a 200 day moving average price of GBX 310.68. The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The stock has a market capitalization of £326.05 million, a P/E ratio of -9.05 and a beta of 1.13.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Featured Stories
- Five stocks we like better than MaxCyte
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- What is the FTSE 100 index?
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
